Earnings — page 2
Sumitomo Mitsui Trust swings net interest income to profit
Consolidated net interest income reached ¥75.58 billion in the first half of fiscal 2026 after a ¥27.85 billion loss a year earlier.
Banco do Brasil Publishes Third-Quarter 2026 MD&A
The Brazilian state-owned lender released its 3Q26 Management Discussion and Analysis covering net interest income, fees, capital and loans.
Tetra Tech Closes Fiscal 2026 With Record Earnings
Fourth-quarter diluted earnings were a record $0.51 a share, and backlog reached $4.67 billion, up 13% from a year earlier.
Taysha Completes BLA-Enabling TSHA-102 Manufacturing Campaign
The company finished a PPQ run that met product and comparability criteria and said cash of $422.8 million funds operations into the second half of 2028.
T1 Energy Narrows Q3 2026 Loss, Sets Preliminary 2027 G1 Production Plan
The solar maker reported $196.6 million in third-quarter 2026 net sales and a $16.4 million Adjusted EBITDA loss after building 326 MW of module inventory for 2027 offtakes.
Spectrum Brands Fourth-Quarter Sales Reverse Prior Growth
Net sales fell 2.8% to $713.2 million as Home & Garden reversed a record third quarter, while adjusted EBITDA rose 10.3% to $69.9 million.
Fermi Signs 600 MW Hyperscaler Deal After Ending TensorWave Lease
An undisclosed investment-grade hyperscaler committed $200 million to start 600 MW at Project Matador in 2027 as Fermi posted a $141.6 million third-quarter loss.
EZCORP Pawn Loans Outstanding Reach a Record $402.8 Million
Fourth-quarter revenue rose 33% to $447.1 million as pawn loans outstanding hit $402.8 million and net income attributable to EZCORP increased 28% to $34.3 million.
EnerSys Misses Sales Range on Currency as Defense Grows
Second-quarter fiscal 2027 net sales were $949.9 million, 0.1% below the year-ago quarter and under the $955 million to $995 million range, while adjusted diluted EPS reached $3.22.
Aveanna Raises 2026 Revenue and Adjusted EBITDA Outlook
Third-quarter revenue reached $695.5 million as the home-care platform lifted full-year revenue guidance to greater than $2.695 billion.
Spire Restores Revenue Growth After Maritime Sale
Third-quarter sales were $18.0 million, up 42% from a year earlier, and $75 million to $80 million is the 2026 revenue outlook.
Sanuwave Q3 Ultramist System Sales Collapse After Proposed CMS Rule
Third-quarter revenue fell 24% to $8.6 million as Ultramist systems dropped to 40 units and the company swung to a $1.4 million net loss.
Sky Harbour Raises 2026 Revenue Outlook, Cuts Ebitda Range
The aviation infrastructure company lifted year-end 2026 revenue guidance to $44 million–$48 million after third-quarter sales rose about 45% from a year earlier.
Sally Beauty Restores Fourth-Quarter Comparable Sales Growth
Fourth-quarter net sales were $953 million and comparable sales rose 0.9% after a flat third quarter.
Satellogic Extends Positive Adjusted EBITDA Streak
Third-quarter revenue hit a record $16.0 million as Space Systems reached $9.5 million and Adjusted EBITDA turned positive for a second straight period.
Ovid's Third-Quarter Loss Widens as Clinical Spend Rises
The biopharmaceutical company posted a $20.8 million net loss, or $0.10 a share, as research and development expenses reached $15.7 million.
Olema's Third-Quarter Loss Widens as Late-Stage Trials Ramp
Olema reported a third-quarter 2026 net loss of $73.6 million, with cash, cash equivalents and marketable securities of $413.8 million as the company said it remained on track for OPERA-01 top-line data in the first quarter of 2027.
Energy Vault Affirms 2026 Revenue Outlook After Cash Rises
Third-quarter revenue was $13.1 million as the company kept 2026 sales guidance at $290 million to $310 million and issued preliminary 2027 revenue of $600 million to $700 million.
LightPath Backlog Reaches Record $132.9 Million
Revenue was $20.8 million in the fiscal 2027 first quarter, with assemblies and modules at 51% of sales and adjusted EBITDA at $1.3 million.
Gladstone Land Participation Rents Reverse Second-Quarter Loss
Adjusted FFO was $15.1 million, or $0.35 a share, after $16.8 million of participation rents as 2025 pistachio bonuses were recognized.
Bitmine's Ethereum Treasury Marks $6.2 Billion Unrealized Loss
Staking and validation generated $121.4 million of the $124.8 million in revenue for the fiscal year ended August 31, 2026.
Exagen Reiterates 2026 Outlook After Slower Third-Quarter Growth
Third-quarter revenue was $18.4 million, up 7% from a year earlier, as year-over-year growth slowed from 16% in the second quarter.
Velo3D Postpones 2026 EBITDA Turn to 2028
Third-quarter revenue was $20.5 million, up 50% from a year earlier, as the company reaffirmed full-year sales of $65 million to $75 million.
Upstream Bio Completes Milestones Ahead of 2027 Phase 3 Start
Cash, cash equivalents and short-term investments stood at $207.4 million as of September 30, 2026, which the company said is expected to fund planned operations through 2027.
TriSalus Cuts 2026 Sales Outlook After TriNav Rebound
The company now sees full-year revenue of $46 million to $48 million after third-quarter TriNav sales of $12.9 million.
TransDigm Beats High End of Guidance on Sales and Ebitda
Fourth-quarter net sales were $2,988 million, and the company issued fiscal 2027 sales guidance of $11,950 million to $12,150 million.
Smart Sand Raises 2026 Volume Outlook After Sequential Sales Dip
Third-quarter revenue was $112.3 million as tons sold fell 4% from a second-quarter record, and the company now expects a 20% to 30% increase in 2026 sales volumes versus 2025.
Silicon Labs Posts First Quarterly GAAP Profit in 2026
Non-GAAP diluted earnings were $1.05 a share as revenue reached $251 million, up 22% from a year earlier.
Chicago Atlantic Adds Koach Notes, Lifts Distributable Earnings
Distributable earnings were $0.49 a share after the company began counting Koach Notes income that GAAP records in equity.
RideNow's Same-Store Sales Reverse After Clear Price Rollout
Third-quarter revenue was $244.3 million, down 13.1%, as adjusted EBITDA fell to $5.3 million and the company reported a larger net loss.
QuickLogic Sequential Revenue Falls After Prior Rise
Third-quarter continuing-operations revenue was $5.1 million, down 6.3% from the second quarter, as new-product sales slipped and GAAP net loss widened to $2.2 million.
D-Wave Locks CHIPS Deal as Remaining Obligations Hit $38.3 Million
Third-quarter revenue was $4.5 million, up 21%, as remaining performance obligations reached $38.3 million and a Commerce agreement opened access to up to $100 million of CHIPS funding.
Protalix Reaffirms 2026 Revenue Range After Chiesi Milestone
Nine-month revenue reached $75.6 million, including a $25.0 million Chiesi milestone, as third-quarter net income rose to $4.0 million.
PepGen Extends Cash Runway Into 2028 After FREEDOM2 Data
Cash, cash equivalents and marketable securities were $104.8 million as of September 30, 2026, and the company said that balance will fund operations into 2028.
Palladyne Raises Low End of 2026 Sales Outlook
Third-quarter revenue reached a record $8.6 million, and the company lifted the low end of 2026 guidance to $25 million while keeping the $27 million top end.
Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Trial
Cash and cash equivalents were $113.6 million as of September 30, 2026, which the company said it believes will fund operations through Phase 2 readouts.
MaxCyte Lifts 2026 Revenue Guidance Excluding Akron Acquisition
Third-quarter revenue reached $10.2 million as the company raised full-year 2026 revenue guidance to at least $34.5 million, excluding the impact of the Akron acquisition, and agreed to buy Akron Bio for $151.8 million.
Mercury Reports Record First-Quarter Fiscal 2027 Revenue and Bookings
Fiscal 2027 first-quarter revenue was a record $253 million, while bookings reached $370 million, up 48.0% from a year earlier, and backlog approached $2.1 billion.
MasterCraft's Legacy Sales Rise 37% After Marine Products Close
Net sales were $154.1 million in the first three months of the transition period ended Oct. 4, 2026, and income from continuing operations was $12.1 million, or $0.50 a share.
908 Devices Raises Low End of 2026 Revenue Range
Third-quarter revenue reached $19.0 million, up 35% from a year earlier, and the company lifted the low end of its 2026 outlook to $68.5 million.
Liquidia Records $389.7 Million Settlement Charge
YUTREPIA net product sales reached $222.7 million in the third quarter as the company booked a $389.7 million litigation settlement charge.
KULR Product Sales Nearly Quadruple After Bitcoin Exit
Third-quarter continuing-operations revenue was $7.40 million, up 197% from a year earlier, as product sales reached $6.49 million.
Inhibikase Activates 79 of 180 Planned IMPROVE-PAH Sites
Cash, cash equivalents and marketable securities were $193.3 million after a $50 million RA Capital sale, and the company said that capital, assuming full and timely exercise of Series A and B warrants, will fund operations through the Part B topline readout.
Humacyte Doubles Symvess Sales After Commercial Rebuild
Third-quarter Symvess sales reached $1.0 million, and the company said it anticipates at least doubling that total in the fourth quarter.
GoPro Cannot File 10-Q, Flags Covenant Risk
The camera maker said it expects third-quarter net revenue of about $96 million and a 12.7% gross margin, and that financial statements will still show substantial doubt about its ability to continue as a going concern.
Gevo Lifts 2026 Adjusted EBITDA Outlook After Record Quarter
Third-quarter revenue hit a record $83 million, including about $29.4 million of Canadian CFR credits, as the company raised its 2026 Adjusted EBITDA target to greater than $90 million.
Electromed Extends Growth Streak as Revenue Pace Cools
Net revenues reached $18.7 million in the fiscal first quarter, up 10.6% from a year earlier, as operating income rose 30.7% to $3.5 million.
CoreWeave Raises 2026 Revenue Guidance After Operating Income Turns Positive
Third-quarter revenue reached $3.66 billion, up more than $1 billion sequentially, as the company lifted full-year sales to as much as $13.3 billion.
Corbus Starts Phase 3 Oropharyngeal Cancer Trial
The clinical-stage company dosed the first TEMPO-1 patient and reported 5% mean weight loss at 12 weeks on 60 mg CRB-913, with cash of $115.3 million expected to fund operations into 2028.
Core & Main Cuts Fiscal 2026 Ebitda Outlook
The specialty distributor now expects fiscal 2026 Adjusted EBITDA of $950 million to $960 million after preliminary third-quarter sales of $2.12 billion to $2.13 billion.